Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placebo-Controlled Double-Blind Study of Rufinamide (E2080) in Lennox-Gastaut Syndrome
2016-004952-30Phase 3
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Lennox-Gastaut syndrome (LGS) comparing rufinamide with placebo (2 arms). Primary endpoint: Percent Change in Tonic-atonic Seizure Frequency From Baseline (Per 28 Days).
02
Drugs
rufinamide
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on 2016-004952-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004952-30.